Clinical Trial · NCT03631017

Imaging With a PET Agent for Detection of Cancers of the Head and Neck

Overview

The purpose of this study is to test the safety of a study drug called PARPi-FL. This drug has been tested in animals but not yet in people. The purpose of this study is to test if a PARPi-FL scan can be used to take pictures of head and neck cancer. The usual approach to imaging this cancer includes several different imaging scans, including x-rays, CT (computed tomography), MRI (magnetic resonance imaging), and PET (positron emission tomography). These tests take pictures of the cancer.

Sponsor

Memorial Sloan Kettering Cancer Center

Phase

Phase 1/2

Contacts

Heiko Schöder, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT03631017

Drug / Compound

PARPi-FL

Isotope(s):

Target(s):

PARP

Ligand Class: Small Molecules

Eligibility

Inclusion

Part 1:
Biopsy (histologically or cytologically) proven Squamos Cell Carcinoma
ECOG performance status 0 or 1
Age ≥18 years
Oral cavity, oropharynx, or nasopharynx primary site

Exclusion

* Significantly impaired organ function that may interfere with the excretion and metabolism of the imaging agent. Specifically, patients will be excluded if they meet the following criteria:
Hepatic
Bilirubin \>2.0 x ULN (institutional upper limits of normal)
Hematologic o Platelets \<75K/mcL
AST/ALT \>2.5 x ULN